Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables: 2015-2019

Historic Notes Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2019 value amounting to $4.0 million.

  • Viridian Therapeutics, Inc.\DE's Notes Payables fell 49.01% to $4.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $4.7 million, marking a year-over-year decrease of 49.01%. This contributed to the annual value of $4.0 million for FY2019, which is 61.39% down from last year.
  • According to the latest figures from FY2019, Viridian Therapeutics, Inc.\DE's Notes Payables is $4.0 million, which was down 61.39% from $10.3 million recorded in FY2018.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Notes Payables registered a high of $10.3 million during FY2018, and its lowest value of $1.1 million during FY2015.
  • Moreover, its 3-year median value for Notes Payables was $9.9 million (2017), whereas its average is $8.1 million.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Notes Payables spiked by 333.39% in 2016 and then tumbled by 61.39% in 2019.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Notes Payables stood at $1.1 million in 2015, then spiked by 333.39% to $4.8 million in 2016, then soared by 107.18% to $9.9 million in 2017, then rose by 3.79% to $10.3 million in 2018, then slumped by 61.39% to $4.0 million in 2019.